title: Pilot experience with opebacan/rBPI 21 in myeloablative hematopoietic cell transplantation.
abstract: Bacterial infection and inflammation contribute significantly to the morbidity and mortality of myeloablative allogeneic hematopoietic cell transplantation (HCT). Endotoxin, a component of the outer membrane of Gram-negative bacteria, is a potent inflammatory stimulus in humans. Bactericidal/permeability increasing protein (BPI), a constituent of human neutrophil granules, binds endotoxin thereby precluding endotoxin-induced inflammation and also has direct anti-infective properties against bacteria. As a consequence of myeloablative therapy used in preparation for hematopoietic cell infusion, patients experience gastrointestinal leak of bacteria and bacterial toxins into the systemic circulation and a period of inflammatory cytokine elevation associated with subsequent regimen-related toxicities.  Patients frequently become endotoxemic and febrile as well as BPI-deficient due to sustained neutropenia. To examine whether enhancing endotoxin-neutralizing and anti-infective activity by exogenous administration of a recombinant N-terminal fragment of BPI (rBPI 21, generic name opebacan) might ameliorate regimen-related toxicities including infection, we recruited patients scheduled to undergo myeloablative HCT to participate in a proof-of-concept prospective phase I/II trial. After the HCT preparative regimen was completed, opebacan was initiated 18-36 hours prior to administration of allogeneic hematopoietic stem cells (defined as Day 0) and continued for 72 hours. The trial was to have included escalation of rBPI 21 dose and duration but was stopped prematurely due to lack of further drug availability.  Therefore, to better understand the clinical course of opebacan-treated patients (n=6), we compared their outcomes with a comparable cohort meeting the same eligibility criteria and enrolled in a non-interventional myeloablative HCT observational study (n = 35).  Opebacan-treated participants had earlier platelet engraftment (p=0.005), mirroring beneficial effects of rBPI 21 previously observed in irradiated mice, fewer documented infections (p=0.03) and appeared less likely to experience significant regimen-related toxicities (p=0.05). This small pilot experience supports the potential utility of rBPI 21 in ameliorating HCT-related morbidity and merits further exploration.
authors.affiliation: Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA; Boston Children's Hospital, Boston, USA.
authors.forename: Eva
authors.initials: E
authors.lastname: Guinan
authors.affiliation: Harvard Medical School, Boston, USA; Beth Israel Deaconess Medical Center, Boston, USA.
authors.forename: David E
authors.initials: DE
authors.lastname: Avigan
authors.affiliation: Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA; Brigham and Women's Hospital, Boston, USA.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Soiffer
authors.affiliation: Children's Hospital of Philadelphia, Philadelphia, USA.
authors.forename: Nancy J
authors.initials: NJ
authors.lastname: Bunin
authors.affiliation: Dana-Farber Cancer Institute, Boston, USA.
authors.forename: Lisa L
authors.initials: LL
authors.lastname: Brennan
authors.affiliation: Boston Children's Hospital, Boston, USA.
authors.forename: Ilana
authors.initials: I
authors.lastname: Bergelson
authors.affiliation: Boston Children's Hospital, Boston, USA.
authors.forename: Spencer
authors.initials: S
authors.lastname: Brightman
authors.affiliation: Harvard Medical School, Boston, USA; Boston Children's Hospital, Boston, USA.
authors.forename: Al
authors.initials: A
authors.lastname: Ozonoff
authors.affiliation: Xoma (US) LLC, Berkeley, USA.
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Scannon
authors.affiliation: Harvard Medical School, Boston, USA; Boston Children's Hospital, Boston, USA.
authors.forename: Ofer
authors.initials: O
authors.lastname: Levy
keywords: allogeneic hematopoietic cell transplantation; endotoxin; engraftment; infection; innate immunity; regimen-related toxicity
references.citation: J Clin Invest. 1995 Apr;95(4):1947-52
references.pmid: 7706502
references.citation: Sci Transl Med. 2011 Nov 23;3(110):110ra118
references.pmid: 22116933
references.citation: Ann Surg. 1994 Jul;220(1):77-85
references.pmid: 8024362
references.citation: J Clin Invest. 2001 Jun;107(12):1581-9
references.pmid: 11413166
references.citation: J Am Coll Cardiol. 1999 Dec;34(7):1975-81
references.pmid: 10588212
references.citation: Bone Marrow Transplant. 2003 Jun;31(12):1137-42
references.pmid: 12796793
references.citation: F1000Res. 2015 Dec 21;4:1480
references.pmid: 26835003
references.citation: Nanomedicine. 2014 Apr;10(3):543-51
references.pmid: 24262996
references.citation: N Engl J Med. 2001 Jan 18;344(3):175-81
references.pmid: 11172139
references.citation: Blood. 2000 Jun 15;95(12):3702-9
references.pmid: 10845900
references.citation: Nat Rev Immunol. 2003 Feb;3(2):169-76
references.pmid: 12563300
references.citation: Nat Med. 2006 Dec;12(12):1365-71
references.pmid: 17115046
references.citation: Biochem Pharmacol. 1994 Apr 29;47(9):1553-9
references.pmid: 8185667
references.citation: Biochem Soc Trans. 2011 Aug;39(4):994-9
references.pmid: 21787336
references.citation: Immunol Res. 2007;39(1-3):249-60
references.pmid: 17917069
references.citation: Pediatr Infect Dis J. 2003 Nov;22(11):978-81
references.pmid: 14614371
references.citation: Transplantation. 2000 Jul 27;70(2):272-9
references.pmid: 10933148
references.citation: J Leukoc Biol. 2004 Nov;76(5):909-25
references.pmid: 15292276
references.citation: J Surg Res. 1996 Jun;63(1):44-8
references.pmid: 8661170
references.citation: J Proteome Res. 2012 Nov 2;11(11):5235-44
references.pmid: 23020738
references.citation: Infect Immun. 1992 Nov;60(11):4754-61
references.pmid: 1398985
references.citation: Infect Immun. 2008 Feb;76(2):454-65
references.pmid: 18086818
references.citation: Antimicrob Agents Chemother. 1996 Jan;40(1):65-9
references.pmid: 8787881
references.citation: J Immunol. 1995 May 15;154(10):5403-10
references.pmid: 7730641
references.citation: Blood. 1992 Dec 15;80(12):2964-8
references.pmid: 1467511
references.citation: Int J Antimicrob Agents. 2013 Dec;42(6):571-4
references.pmid: 24189329
references.citation: Shock. 1998 Sep;10(3):161-6; discussion 167-8
references.pmid: 9744643
references.citation: J Endotoxin Res. 2001;7(5):335-48
references.pmid: 11753202
references.citation: Infect Immun. 2007 Jan;75(1):342-9
references.pmid: 17101667
references.citation: Antimicrob Agents Chemother. 2000 Nov;44(11):2925-31
references.pmid: 11036002
references.citation: Transplantation. 1974 Oct;18(4):295-304
references.pmid: 4153799
references.citation: Clin J Am Soc Nephrol. 2008 Mar;3(2):431-6
references.pmid: 18256376
references.citation: Lancet. 2000 Sep 16;356(9234):961-7
references.pmid: 11041396
references.citation: J Clin Invest. 1998 Nov 15;102(10):1882-91
references.pmid: 9819375
references.citation: Shock. 1996 Feb;5(2):91-6
references.pmid: 8705395
references.citation: Innate Immun. 2014 Oct;20(7):697-711
references.pmid: 24107515
references.citation: Blood. 1995 Jun 15;85(12):3437-43
references.pmid: 7780131
references.citation: J Clin Invest. 1990 Mar;85(3):853-60
references.pmid: 2179269
references.citation: Lancet. 2001 Mar 3;357(9257):675-9
references.pmid: 11247551
references.citation: J Clin Invest. 1992 Sep;90(3):1122-30
references.pmid: 1522221
references.citation: Curr Opin Immunol. 1999 Feb;11(1):19-22
references.pmid: 10047547
references.citation: J Endotoxin Res. 2002;8(6):441-8
references.pmid: 12697087
references.citation: Philos Trans R Soc Lond B Biol Sci. 2005 Sep 29;360(1461):1747-67
references.pmid: 16147539
references.citation: Blood. 2006 Mar 1;107(5):2200-7
references.pmid: 16304058
references.citation: Bone Marrow Transplant. 2007 Jul;40(1):63-70
references.pmid: 17468772
references.citation: Antimicrob Agents Chemother. 1999 Sep;43(9):2314-6
references.pmid: 10471588